ArticleFrontiers in oncology2025
Patient-derived cell lines unveil COL1A2 as a predictor of docetaxel resistance in breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural G-Quadruplex Stabilizers: A Targeted Strategy for Breast Cancer Therapy.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is the most common malignant tumor among women worldwide and a major cause of cancer-related mortality. Chemoresistance presents a significant challenge in breast cancer therapy and is a primary driver of tumor recurrence and metastasis. However, effective predictive strategies for chemoresistance remain limited. This study aimed to investigate the mechanisms and predictive models underlying chemotherapy resistance in HR+/HER2- breast cancer. Methods: Patient-derived primary cancer cell lines (PCCLs) were successfully established from four patients with HR+/HER2- breast cancer (Luminal B, HER2 non-amplified) using primary cell culture techniques. The retention of the original tumors' pathological characteristics and drug response heterogeneity was confirmed. The sensitivities of PCCLs to taxanes, including docetaxel, were evaluated. RNA sequencing followed by protein-protein interaction (PPI) network analysis was performed to identify candidate genes associated with docetaxel resistance. The expression of COL1A2 was then correlated with pathological complete response (pCR) and recurrence-free survival (RFS) in patients who received neoadjuvant chemotherapy (AC-T regimen). Functional assays were conducted to assess the impact of COL1A2 expression on docetaxel sensitivity in HR+/HER2- breast cancer cells. Results: PCCLs derived from HR+/HER2- breast cancer exhibited heterogeneous sensitivity to taxanes, including docetaxel. RNA sequencing and PPI network analysis identified COL1A2 as significantly overexpressed in HR+/HER2- breast cancer patients with docetaxel resistance. Elevated COL1A2 expression showed a negative correlation with pCR rates and RFS. In functional assays, higher COL1A2 expression was associated with reduced sensitivity to docetaxel in HR+/HER2- breast cancer cells. These findings were consistent with imaging assessments and postoperative pathological outcomes in patients who underwent neoadjuvant AC-T therapy. Discussion: Our findings indicate that COL1A2 is associated with reduced chemotherapy sensitivity in HR+/HER2- breast cancer and may serve as a candidate biomarker to guide neoadjuvant taxane selection. This study provides a novel theoretical basis for optimizing neoadjuvant chemotherapy regimens in patients with advanced HR+/HER2- breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.